<DOC>
	<DOCNO>NCT02015351</DOCNO>
	<brief_summary>Efficacy monthly intravitreal anti-vascular endothelial growth factor ( VEGF ) associate systemic immunosuppression patient Vogt-Koyanagi-Harada Disease choroidal neovascularization . Minimum follow-up 12 month . Endpoints : 6 12 month follow-up . Outcome measure : improvement VA , decrease central foveal thickness measure Optical Coherence Tomography ( OCT ) absence intra/subretinal fluid .</brief_summary>
	<brief_title>Intravitreal Bevacizumab Treatment CNV VKH Disease - A Prospective Study</brief_title>
	<detailed_description>Choroidal neovascularization ( CNV ) Vogt-Koyanagi-Harada ( VKH ) disease associate poor visual prognosis . Several treatment suggest , though still standard therapy . CNV diagnosis base fundus biomicroscopy ( presence serous retinal detachment without retinal hemorrhage ) , fluorescein angiography ( FA ) ( presence early phase hyperfluorescence late phase leakage ) OCT finding ( hyperreflective lesion relate CNV complex serous foveal detachment intraretinal fluid increase foveal thickness ) . Inflammation consider active anterior chamber cell optic disc leakage FA observe . Each patient undergo complete clinical exam , include best correct visual acuity ( VA ) ( Snellen chart ) . Once active CNV identify , load dose 3 injection IV bevacizumab proceed monthly systemic immunosuppression introduce intensify . After first 3 injection , patient clinically examine OCT proceed monthly . The persistence intra/subretinal fluid OCT indicate one IV bevacizumab injection . Immunosuppression status evaluation do 3 , 6 , 9 12 month follow intensification do inflammatory sign persistence intraretinal fluid observe . Presence intra/subretinal fluid manual measurement retina central foveal thickness ( CFT ) proceed horizontal scan examiner .</detailed_description>
	<mesh_term>Choroidal Neovascularization</mesh_term>
	<mesh_term>Neovascularization , Pathologic</mesh_term>
	<mesh_term>Uveomeningoencephalitic Syndrome</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>1 . Patients diagnose VogtKoyanagiHarada disease base Revised Diagnostic Criteria present International Committee VKH disease 2001 ; 2 . Presence choroidal neovascularization identify fundus biomicroscopy , fluorescein angiography OCT. Media opacities preclude posterior segment exam , ametropia 5 dioptries , glaucoma ( defined disease characteristic damage optic nerve characteristic visual field defect compatible nerve fiber layer lesion ) , Age relate Macular degeneration , impossibility increase immunosuppression .</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Choroidal neovascularization</keyword>
	<keyword>Vogt Koyanagi Harada Disease</keyword>
	<keyword>Inflammatory choroidal neovascularization</keyword>
	<keyword>Anti-VEGF</keyword>
</DOC>